REGNRegeneron PharmaceuticalsSigning up patients
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma (CSCC)
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 3
- Patients
- 369 (planned)
- Started
- Jan 2, 2025
- Main results expected
- May 3, 2030
- Fully finished
- May 3, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Event-Free Survival (EFS) as assessed by the investigator
Measured over: Up to 1 year
EFS as assessed by the investigator
Measured over: Up to 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06585410 · record last updated 2026-09-16 · checked 2026-11-09 15:47 UTC